HPLC Detection Methods of Four Anticoagulants

Through the HPLC detection method, the problem of detecting four anticoagulants simultaneously was successfully solved using specific mobile phase and chromatographic column conditions, and the rapid and accurate detection in complex protein buffers was achieved, with good application prospects.

CN115963218BActive Publication Date: 2024-11-26ZHENGZHOU IMMUNO BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211621936.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-16
Publication Date
2024-11-26
Estimated Expiration
2042-12-16

AI Technical Summary

Technical Problem

Existing detection methods cannot detect four anticoagulants quickly and accurately simultaneously, especially under the complex components of protein buffers in the biological industry, lacking methods to meet the needs.

Method used

Using HPLC detection method, the cylinder pH is adjusted to 2.15 through specific mobile phase and elution procedures, combined with Agilent Inertsil ODS-SP C18 chromatography column, and the separation of four anticoagulants is achieved by using aqueous phosphoric acid solution and methanol as mobile phase. Tests include sodium citrate, sodium oxalate, sodium heparin and EDTA.2Na.

Benefits of technology

It realizes the rapid and accurate detection of four anticoagulants, has good resolution and anti-interference ability, and can be stably detected in the presence of different protein buffer systems and stabilizers. It has a wide linear range, high accuracy, repeatability and precision. Strong.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115963218B_ABST
    Figure CN115963218B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biochemical detection, and specifically relates to an HPLC detection method for four anticoagulants. The present invention discloses an HPLC method for quickly detecting anticoagulants in a protein buffer, wherein the anticoagulants include sodium citrate, sodium oxalate, sodium heparin and EDTA.2Na. The HPLC detection method of the present invention can be used for qualitative detection of anticoagulants, and can be used for quantitative detection of sodium citrate and EDTA.2Na. The method is highly specific, simple, rapid, accurate, and has good separation. The measurement results are accurate and reliable, and the type of anticoagulant can be quickly determined, and the method has good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biochemical detection, and in particular relates to an HPLC detection method for four anticoagulants. Background Art

[0002] Anticoagulants mainly use physical or chemical methods to remove or inhibit certain coagulation factors in the blood, prevent blood from coagulating, and achieve the purpose of anticoagulation. They can be divided into four types: citrate, oxalate, heparin and EDTA. Among them, citrate and EDTA can both bind to calcium ions to form chelates, thereby preventing blood from coagulating; oxalate can bind to calcium ions to form precipitation, thereby preventing blood from coagulating; and heparin can enhance antithrombin III (AT-III) to inactivate serine proteases, thereby preventing the formation of thrombin. In addition to being used as anticoagulants, anticoagulants are also one of the commonly used reagents. They are used in biology and chemistry mainly as complexing agents, buffers, etc. Some anticoagulants are often added to protein buffers as complexing agents to remove some metal ions, prevent metal ions from destroying the structure and activity of proteins, and maintain the stability of proteins.

[0003] GB and Pharmacopoeia detection methods for citrate include chemical detection method and HPLC detection, among which HPLC detection includes ion exchange method and reverse phase method; GB and Pharmacopoeia detection methods for oxalate are mainly chemical detection method and reverse phase HPLC detection; Pharmacopoeia detection methods for heparin include anion exchange chromatography column, and GB and Pharmacopoeia detection methods for EDTA include chemical detection method and reverse phase HPLC detection. However, these detection methods are all for the detection of a specific type of anticoagulant, and there is no method that can meet the requirements of detecting four types of anticoagulants at the same time. In addition, for the biological industry, anticoagulants are used as complexing agents in protein buffers, and the composition is relatively complex, so rapid and accurate detection methods are more needed. Therefore, seeking a method that can effectively separate and quickly detect anticoagulants in protein buffers is of great significance for further quality control of samples. Summary of the invention

[0004] In view of this, the technical problem to be solved by the present invention is to provide an HPLC detection method for four anticoagulants.

[0005] The present invention provides an HPLC detection method for anticoagulants, which comprises: filtering a sample and then detecting it by HPLC:

[0006] The detection conditions of the HPLC include:

[0007] Mobile phase A: phosphoric acid aqueous solution with a pH value of 2 to 3;

[0008] Mobile phase B: methanol;

[0009] The elution procedure is:

[0010] From 0 to 20 min, the volume fraction of mobile phase A was 99% to 90%;

[0011] From 20 to 25 min, the volume fraction of mobile phase A was from 90% to 10%;

[0012] From 25 to 35 min, the volume fraction of mobile phase A was 10%;

[0013] From 35 to 40 min, the volume fraction of mobile phase A ranged from 10% to 99%;

[0014] From 40 to 50 minutes, the volume fraction of mobile phase A was 99%.

[0015] Further, in the HPLC detection method,

[0016] Mobile phase A was aqueous phosphoric acid with a pH of 2.15;

[0017] The chromatographic column is an Agilent Inertsil ODS-SP C18 chromatographic column, wherein the Agilent Inertsil ODS-SPC18 chromatographic column has a length of 4.6 mm and an inner diameter of 250 mm, and the filler is octadecylsilane bonded silica gel, and the filler particle size is 5 μm;

[0018] The injection volume was 5 μL, the column temperature was 30 °C, and the flow rate was 1.0 ml / min.

[0019] The detection wavelength is 210 nm.

[0020] In the present invention, the chromatographic column needs to use a phosphoric acid solution to adjust the column pH to 2.15 before injection.

[0021] In the present invention, the anticoagulant includes sodium citrate, sodium oxalate, sodium heparin and EDTA.2Na.

[0022] In the present invention, the four anticoagulants separated by the HPLC detection method have different peak times and have strong specificity; at the same time, the HPLC detection method of the present invention can avoid the influence of different protein buffer systems, different protein stabilizers, and different buffer system proteins, and stably realize the rapid detection of the four anticoagulants. The detection results are accurate and the separation degree is good, and it has good application prospects.

[0023] In the present invention, the protein stabilizer includes a surfactant and an antioxidant. The surfactant includes a cationic surfactant, an anionic surfactant and a nonionic detergent; the cationic surfactant includes but is not limited to S8 and / or benzalkonium bromide; the anionic surfactant includes but is not limited to SDS; the nonionic detergent includes but is not limited to Triton. The antioxidant includes but is not limited to DTT and or β-mercaptoethanol.

[0024] The method provided by the present invention has good anti-interference ability. Experiments show that the presence of 0.1% SDS, 1% Tritonx-100, 0.1% S8 or 5mM DTT does not affect the detection of the four immunosuppressants.

[0025] In the different buffer system proteins of the present invention, the proteins include but are not limited to BSA or other proteins contained in the test sample, which is not limited in the present invention. In some specific embodiments of the present invention, the presence of 2% BSA does not affect the detection of the four immunosuppressants.

[0026] In the present invention, the buffer system includes but is not limited to PBS buffer system, Tris buffer system and KCl buffer system. In some specific embodiments of the present invention, the presence of 20mM Tris, 10mM PBS or 10mM KCl does not affect the detection of the four immunosuppressants.

[0027] In the present invention, the HPLC detection method further comprises the preparation of a standard solution: sodium citrate, sodium oxalate, sodium heparin and EDTA.2Na reagent are dissolved in water to obtain a standard solution.

[0028] In the present invention, the calculation method of the anticoagulant content in the HPLC detection method is:

[0029] Using high performance liquid chromatography, chromatograms of the anticoagulant in the sample and standard solution were obtained under the same detection conditions;

[0030] According to the concentration of the anticoagulant in the standard solution, the peak area of ​​the standard in the chromatogram, and the peak area of ​​the component corresponding to the standard in the sample in the chromatogram, and based on the detection method of the present invention, the content of the anticoagulant is calculated by the external standard two-point method.

[0031] In the HPLC detection method of the present invention, the linear range of the anticoagulant includes:

[0032] The linear range of sodium citrate is 0.1mM to 10mM;

[0033] The linear range of EDTA.2Na is 0.03mM~0.7mM;

[0034] The linear range of sodium oxalate is 0.04mM~80mM;

[0035] The linear range of heparin sodium is 0.04mg / ml~1mg / ml.

[0036] The HPLC detection method of the present invention has a wide linear range and high accuracy. In some specific embodiments, the linear range of sodium citrate is 0.1mM-10mM, the limit of quantification is 0.08mM (signal-to-noise ratio 10:1), and the detection limit is 0.05mM (signal-to-noise ratio 3:1); the linear range of EDTA.2Na is 0.03mM-0.7mM, the limit of quantification is 0.02mM (signal-to-noise ratio 10:1), and the detection limit is 0.01mM (signal-to-noise ratio 3:1); the linear range of sodium oxalate is 0.04mM-80mM, the limit of quantification is 0.01mM (signal-to-noise ratio 10:1), and the detection limit is 0.004mM (signal-to-noise ratio 3:1); the linear range of heparin sodium is 0.04mg / ml-1mg / ml, the limit of quantification is 0.02mg / ml (signal-to-noise ratio 10:1), and the detection limit is 0.014mM (signal-to-noise ratio 3:1).

[0037] The HPLC detection method of the present invention has strong repeatability and high precision.

[0038] In some specific embodiments, 5mM sodium citrate, 0.4mM EDTA.2Na, 0.4mM sodium oxalate, and 0.5mM sodium heparin were repeated 6 times, and the relative standard deviations (RSDs) thereof were 0.35%, 0.63%, 0.38%, and 0.1%, respectively, demonstrating that the HPLC detection method has good repeatability.

[0039] In other specific embodiments, 3.4 mM sodium citrate, 0.3 mM EDTA.2Na, 1 M sodium oxalate, and 0.7 mg / ml heparin sodium were tested six times, and the relative standard deviations of their contents were 0.75%, 0.79%, 0.30%, and 0.13%, respectively, indicating that the experiment had good precision.

[0040] In the present invention, samples for HPLC detection method include but are not limited to buffer, serum or plasma, and the present invention does not limit this.

[0041] The invention discloses an HPLC method for quickly detecting an anticoagulant in a protein buffer, wherein the anticoagulant includes sodium citrate, sodium oxalate, sodium heparin and EDTA.2Na. The HPLC detection method of the invention can detect the anticoagulant qualitatively and can detect sodium citrate and EDTA.2Na quantitatively. The method has strong specificity, is simple, rapid, accurate, has good separation, and the measurement result is accurate and reliable. The type of anticoagulant can be quickly determined, and the method has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 Shows the HPLC specificity test of four anticoagulants;

[0043] Figure 2 HPLC detection of four anticoagulants in the presence of different stabilizers for protein buffering is shown;

[0044] Figure 3 Shown is the HPLC detection of four anticoagulants in different protein buffer systems;

[0045] Figure 4 The HPLC test of four anticoagulants with different protein additives in protein buffer is shown;

[0046] Figure 5 HPLC detection standard curve of sodium citrate is shown;

[0047] Figure 6 The HPLC standard curve of EDTA.2Na is shown;

[0048] Figure 7 The HPLC standard curve of sodium oxalate is shown;

[0049] Figure 8 It shows the HPLC standard curve of heparin sodium;

[0050] Fig. 9 Shows the repeatability test of sodium citrate HPLC;

[0051] Fig.10 Shows EDTA.2Na HPLC repeatability test;

[0052] Fig.11 Shows the repeatability test of sodium oxalate HPLC;

[0053] Fig.12 Shows the HPLC recovery of sodium citrate;

[0054] Fig.13 Shows EDTA.2Na HPLC recovery;

[0055] Fig.14 The HPLC recovery rate of sodium oxalate is shown;

[0056] Fig.15 4 shows the HPLC detection spectrum of sodium citrate;

[0057] Fig.16 The HPLC detection spectra of four anticoagulants are shown, and the separation degrees are 3.89, 11.74, and 6.42 respectively;

[0058] Fig.17 The spectrum of four anticoagulants + tris + PBS + KCl buffer is shown;

[0059] Fig.18 The spectra of four anticoagulants + BSA are shown;

[0060] Fig.19 The spectra of four anticoagulants + surfactant + DTT are shown;

[0061] Fig. 20 The peak spectrum of the optimized liquid phase conditions is shown, and the separation degrees are 3.71, 11.68, and 6.34 respectively;

[0062] Fig.21 The two peak spectra of the optimized liquid phase conditions are shown, and the separation degrees are 2.23, 8.31, and 3.74 respectively;

[0063] Fig. 22 The three peak spectra after optimization of liquid phase conditions are shown, with separation degrees of 2.23, 8.29, and 3.71, respectively. DETAILED DESCRIPTION

[0064] The present invention provides four HPLC detection methods for anticoagulants. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0065] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0066] The present invention will be further described below in conjunction with embodiments:

[0067] Example 1 A HPLC Detection Method for Rapid Detection of Four Anticoagulants in Protein Buffer (1) Optimization of Liquid Phase Conditions

[0068] Solution preparation: Preparation of test solution: Weigh sodium citrate, sodium oxalate, sodium heparin and EDTA.2Na accurately, place in a volumetric flask, add ultrapure water, and dissolve the sample completely at room temperature to make the concentrations of sodium citrate 0.1mM~10mM; sodium oxalate 0.04mM~80mM; sodium heparin 0.04mg / ml~1mg / ml; EDTA.2Na 0.03mM~0.7mM. Filter with a 0.22μm water filter membrane and take the filtrate as the test solution.

[0069] Determination: Accurately measure 5 μl of the test solution and sample anticoagulant and inject them into the liquid chromatograph. Determine under the following chromatographic conditions and record the chromatogram.

[0070] Condition optimization 1: Agilent 1260 HPLC, chromatographic column: Agilent Inertsil ODS-SPC18, 5μm, 4.6mm×250mm, octadecylsilane bonded silica gel as filler, phosphoric acid aqueous solution (adjusted to pH 2.15 with phosphoric acid)-methanol as mobile phase; column temperature: 30℃; detection wavelength: 210nm; flow rate: 1.2ml / min; injection volume: 5μl. The elution procedure is shown below, and the spectra of the four anticoagulants are shown below. Fig. 20 As shown, the separation degrees are 3.71, 11.68, and 6.34 respectively.

[0071]

[0072]

[0073] Condition optimization 2: Agilent 1260 HPLC, chromatographic column: Agilent Inertsil ODS-SPC18, 5μm, 4.6mm×250mm, octadecylsilane bonded silica gel as filler, phosphoric acid aqueous solution (adjusted to pH 2.15 with phosphoric acid)-methanol as mobile phase; column temperature: 30℃; detection wavelength: 210nm; flow rate: 1.0ml / min; injection volume: 5μl. The elution procedure is shown below, and the spectra of the four anticoagulants are shown below. Fig.21 As shown, the separation degrees are 2.23, 8.31, and 3.74 respectively.

[0074] Time (minutes) Phosphoric acid aqueous solution pH 2.15 (%) Methanol(%) 0 95 5 20 90 10 25 10 90 35 10 90 40 95 5 50 95 5

[0075] Condition optimization 3: Agilent 1260 HPLC, chromatographic column: Agilent Inertsil ODS-SPC18, 5μm, 4.6mm×250mm, octadecylsilane bonded silica gel as filler, phosphoric acid aqueous solution (adjusted to pH 2.15 with phosphoric acid)-methanol (95:5) as mobile phase; column temperature: 30℃; detection wavelength: 210nm; flow rate: 1.0ml / min; injection volume: 5μl. The elution procedure is shown below. The spectra of the four anticoagulants are as follows Fig. 22 As shown, the separation degrees are 2.23, 8.29, and 3.71 respectively.

[0076] Time (minutes) Phosphoric acid aqueous solution pH 2.15 (%) Methanol(%) 0 95 5 20 95 5 25 10 90 35 10 90 40 95 5 50 95 5

[0077] Condition optimization 4: Agilent 1260 HPLC, chromatographic column: Agilent Inertsil ODS-SPC18, 5μm, 4.6mm×250mm, octadecylsilane bonded silica gel as filler, phosphoric acid aqueous solution (adjusted to pH 2.15 with phosphoric acid)-methanol as mobile phase; column temperature: 30℃; detection wavelength: 210nm; flow rate: 1.0ml / min; injection volume: 5μl. The elution procedure is shown below, and the spectra of the four anticoagulants are shown below. Fig.16 shown.

[0078]

[0079]

[0080] Fig.15 The peak time of the sample was consistent with that of the sodium citrate standard, indicating that the anticoagulant component in the protein buffer was sodium citrate. The HPLC detection spectra of the four anticoagulants are shown in Figure 2. Fig.16 As shown, the separation degrees are 3.89, 11.74, and 6.42 respectively, and the separation effect is good.

[0081] From the above results, it can be seen that the liquid phase condition of condition optimization 4 has the best separation and is used in subsequent verification.

[0082] Example 2 Methodological verification of HPLC detection methods for four anticoagulants

[0083] 1. Specificity test

[0084] Take 7.5mM sodium citrate, 10mM sodium oxalate, 1mg / ml heparin sodium and 5mM EDTA.2Na reagents respectively, filter them with a 0.22μm water filter membrane, take the filtrate for machine detection, and perform chromatographic analysis according to the chromatographic conditions, such as Figure 1 As shown in the results, the peak times of the four anticoagulants are different.

[0085] 2. Identification of protein buffer additives:

[0086] 2.1 Identification of protein stabilizers in protein buffers:

[0087] Other reagents are often added to the protein buffer to maintain the stability of the protein. To eliminate the influence of other reagents, 5mM reducing agent DTT, anionic surfactant 0.1% SDS, nonionic surfactant 1% Tritonx-100, 1% benzalkonium bromide, and 0.1% cationic surfactant S8 were taken respectively, filtered with a 0.22μm water filter membrane, and the filtrate was taken for machine detection and chromatographic analysis was performed according to the chromatographic conditions, such as Figure 2 As shown, the peak spectrum of the additive and anticoagulant after mixing is as follows Fig.19As shown in the results, the peak times of these five additives are different from those of the four anticoagulants.

[0088] 2.2 Identification of different protein buffer systems:

[0089] PBS system, Tris system and KCl are often used in protein buffer. To eliminate the influence of buffer, take 20mM Tris, 10mM PBS and 10mM KCl respectively, filter them with 0.22μm water filter membrane, take the filtrate for machine detection, and perform chromatographic analysis according to chromatographic conditions, such as Figure 3 The peaks of the four anticoagulants in this protein buffer are shown in Fig.17 As shown in the results, it can be seen that these three system components have no peaks.

[0090] 2.3 Protein Identification in Protein Buffer

[0091] BSA additive is needed in protein buffer. To eliminate the influence of protein, take 2% BSA aqueous solution, filter it with 0.22μm water filter membrane, take the filtrate for machine detection, and perform chromatographic analysis according to chromatographic conditions, such as Figure 4 As shown, the peaks of the four anticoagulants when adding this protein are as follows Fig.18 As shown in the results, BSA did not elute.

[0092] 3. Limit of quantification and detection limit

[0093] Detection limit of sodium citrate: prepare 100mM sodium citrate mother solution, dilute it with ultrapure water to 10mM, 7.5mM, 5mM, 2.5mM, 1mM and 0.1mM to prepare standard products, filter it with a 0.22μm water filter membrane, take the filtrate for on-machine detection, perform chromatographic analysis according to the chromatographic conditions, record the peak area, draw a standard curve, use concentration as the horizontal axis and peak area as the vertical axis, draw a standard curve, and calculate the regression equation as follows: Figure 5 As shown. From the results, we can see that the standard curve y = 63.367x + 9.8323, R 2 The linear range is 0.1mM-10mM, the limit of quantification is 0.08mM (signal-to-noise ratio 10:1), and the detection line is 0.05mM (signal-to-noise ratio 3:1), which proves that the method of the present invention has a wide linear range and high accuracy.

[0094] Detection limit of EDTA.2Na: prepare 10mM EDTA.2Na, dilute it with ultrapure water to 7mM, 6mM, 5mM, 4mM, 3mM, 2mM, 1mM, 0.05mM, 0.03mM to prepare standard products, filter it with a 0.22μm water filter membrane, take the filtrate for on-machine detection, perform chromatographic analysis according to the chromatographic conditions, record the peak area, draw a standard curve, use concentration as the horizontal axis and peak area as the vertical axis, draw a standard curve, and calculate the regression equation as follows: Figure 6 As shown in the results, we can know that the calibration curve y = 395.33x-2.0272, R 2 The linear range is 0.03mM-0.7mM, the limit of quantification is 0.02mM (signal-to-noise ratio 10:1), and the detection line is 0.01mM (signal-to-noise ratio 3:1), which proves that the method of the present invention has a wide linear range and high accuracy.

[0095] Sodium oxalate detection limit: prepare 100mM sodium oxalate, dilute it with ultrapure water to 80mM, 40mM, 20mM, 1mM, 0.1mM, 0.04mM to prepare standard products, filter it with a 0.22μm water filter membrane, take the filtrate for on-machine detection, perform chromatographic analysis according to the chromatographic conditions, record the peak area, draw a standard curve, use concentration as the horizontal axis and peak area as the vertical axis, draw a standard curve, and calculate the regression equation as follows: Figure 7 As shown in the results, we can know that the calibration curve y = 349.6x + 89.605, R 2 The linear range is 0.04mM~80mM, the limit of quantification is 0.01mM (signal-to-noise ratio 10:1), and the limit of detection is 0.004mM (signal-to-noise ratio 3:1), which proves that the method of the present invention has a wide linear range and high accuracy.

[0096] Detection limit of heparin sodium: prepare 10 mg / ml of heparin sodium, dilute it with ultrapure water to 1 mg / ml, 0.8 mg / ml, 0.6 mg / ml, 0.4 mg / ml, 0.1 mg / ml, 0.04 mg / ml to prepare standard, filter it with a 0.22 μm water filter membrane, take the filtrate for detection, perform chromatographic analysis according to the chromatographic conditions, record the peak area, draw a standard curve, use concentration as the horizontal axis and peak area as the vertical axis, draw a standard curve, and calculate the regression equation as follows: Figure 8 As shown in the results, we can know that the calibration curve y = 3741.7x + 95.697, R 2 The linear range is 0.04 mg / ml-1 mg / ml, the limit of quantification is 0.002 mM (signal-to-noise ratio 10:1), and the limit of detection is 0.014 mg / ml (signal-to-noise ratio 3:1), which proves that the method of the present invention has a wide linear range and high accuracy.

[0097] 4. Repeatability test

[0098] Repeatability of sodium citrate detection: Prepare 5mM sodium citrate, take 6 samples from the same batch, prepare them according to the preparation method of the test solution, inject 5μL, measure the peak area, and calculate. The RSD of sodium citrate content is 0.35%, which proves that the method of the present invention has good repeatability, as shown in Table 1 and Fig. 9 shown.

[0099] Table 1 Repeatability of sodium citrate detection

[0100]

[0101] Repeatability of EDTA.2Na detection: Prepare 0.4mM EDTA.2Na, take 6 samples from the same batch, prepare them according to the preparation method of the test solution, inject 5μL, measure the peak area, and calculate. The RSD of sodium citrate content is 0.63%, which proves that the method of the present invention has good repeatability. The results are shown in Table 2 and Fig.10 shown.

[0102] Table 2 EDTA.2Na detection repeatability

[0103]

[0104]

[0105] Repeatability of sodium oxalate detection: Prepare 0.4mM sodium oxalate, take 6 samples from the same batch, prepare them according to the preparation method of the test solution, inject 5μL, measure the peak area, and calculate. The RSD of sodium oxalate content was 0.38%, which proves that the method of the present invention has good repeatability. The results are shown in Table 3 and Fig.11 shown.

[0106] Table 3 Repeatability of sodium oxalate detection

[0107]

[0108] Repeatability of heparin sodium test: Prepare 0.5mM heparin sodium, take 6 samples from the same batch, prepare them according to the preparation method of the test solution, inject 5μL, measure the peak area, and calculate. The RSD of sodium oxalate content is 0.1%, which proves that the method of the present invention has good repeatability. The results are shown in Table 4.

[0109] Table 4 Repeatability of heparin sodium test

[0110]

[0111] 5. Recovery rate test

[0112] Prepare 3.4mM sodium citrate, take 6 samples from the same batch, prepare them according to the preparation method of the test solution, inject 5μL, measure the peak area, calculate the injection volume and the recovery after detection. After testing, the relative standard deviation of the sodium citrate content is 0.75%, indicating that the precision of this experiment is good, as shown in Table 5 and Fig.12 shown.

[0113] Table 5 Sodium citrate recovery

[0114]

[0115] EDTA.2Na recovery rate: Prepare EDTA.2Na 0.3mM, take 6 samples from the same batch, prepare them according to the preparation method of the test solution, inject 5μL, measure the peak area, and calculate. The RSD of sodium citrate content was 0.79%, indicating that the precision of this experiment is good, as shown in Table 6 and Fig.13 shown.

[0116] Table 6 EDTA.2Na recovery

[0117]

[0118] Sodium oxalate recovery rate: Prepare 0.8mM sodium oxalate, take 6 samples from the same batch, prepare them according to the preparation method of the test solution, inject 5μL, measure the peak area, and calculate. The RSD of sodium citrate content was 0.30%, indicating that the precision of this experiment is good, as shown in Table 7 and Fig.14 shown.

[0119] Table 7 Sodium oxalate recovery

[0120]

[0121]

[0122] Heparin sodium recovery rate: Prepare heparin sodium 0.7 mg / ml, take 6 samples from the same batch, prepare them according to the preparation method of the test solution, inject 5 μL, measure the peak area, and calculate. The RSD of sodium citrate content was 0.13%, indicating that the precision of this experiment is good, as shown in Table 8.

[0123] Table 8 Heparin sodium recovery

[0124]

[0125] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. The HPLC detection method of anticoagulants is characterized in that: After filtering, the sample was tested by HPLC, and the anticoagulant was sodium citrate, sodium oxalate, sodium heparin and EDTA.2Na; The detection conditions of the HPLC include: Mobile phase A: phosphoric acid aqueous solution with a pH value of 2 to 3; Mobile phase B: methanol; The elution procedure is: From 0 to 20 min, the volume fraction of mobile phase A was 99% to 90%; From 20 to 25 min, the volume fraction of mobile phase A was from 90% to 10%; From 25 to 35 min, the volume fraction of mobile phase A was 10%; From 35 to 40 min, the volume fraction of mobile phase A ranged from 10% to 99%; From 40 to 50 min, the volume fraction of mobile phase A was 99%; The HPLC chromatographic column is an Agilent Inertsil ODS-SP C18 chromatographic column; the Agilent Inertsil ODS-SP C18 chromatographic column has a size of 4.6 mm×250 mm, and the filler is octadecylsilane bonded silica gel, and the filler particle size is 5 μm; In the HPLC detection method, the injection volume was 5 μL, the column temperature was 30°C, and the flow rate was 1.0 ml / min; The HPLC detection wavelength is 210 nm.

2. The HPLC detection method according to claim 1, characterized in that The mobile phase A is a phosphoric acid aqueous solution with a pH value of 2.

15.

3. The HPLC detection method according to claim 1, characterized in that The HPLC detection method further comprises the preparation of a standard solution: sodium citrate, sodium oxalate, sodium heparin and EDTA.2Na reagent are dissolved in water to obtain a standard solution.

4. The HPLC detection method according to claim 1, characterized in that The calculation method of the anticoagulant content in the HPLC detection method is: Using high performance liquid chromatography, chromatograms of the anticoagulant in the sample and standard solution were obtained under the same detection conditions; According to the concentration of the anticoagulant in the standard solution, the peak area of ​​the standard in the chromatogram, and the peak area of ​​the component corresponding to the standard in the sample in the chromatogram, and based on the detection conditions described in claim 1, the content of the anticoagulant is calculated by the external standard two-point method.

5. The HPLC detection method according to claim 1, characterized in that The linear range of anticoagulants includes: The linear range of sodium citrate is 0.1mM to 10mM; The linear range of EDTA.2Na is 0.03mM~0.7mM; The linear range of sodium oxalate is 0.04mM~80mM; The linear range of heparin sodium is 0.04mg / ml~1mg / ml.

6. The HPLC detection method according to claim 1, characterized in that The sample is a protein buffer.